CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
By Elana Gotkine HealthDay Reporter
THURSDAY, April 25, 2024 -- For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by haploidentical hematopoietic stem-cell transplantation (HSCT) is safe and effective, with remission seen for most patients, according to a study published in the April 25 issue of the New England Journal of Medicine.
Yongxian Hu, M.D., Ph.D., from the Zhejiang University School of Medicine in Hangzhou, China, and colleagues tested a novel all-in-one strategy comprising sequential CD7 CAR T-cell therapy and haploidentical HSCT in 10 patients with relapsed or refractory CD7-positive leukemia or lymphoma. Patients received haploidentical HSCT without pharmacologic myeloablation or graft-versus-host-disease (GVHD) prophylaxis drugs after CAR T-cell therapy led to complete remission with incomplete hematologic recovery.
The researchers found that all 10 patients had complete remission with incomplete hematologic recovery and grade 4 pancytopenia after CAR T-cell therapy. One patient died of septic shock and encephalitis on day 13 after haploidentical HSCT; eight patients had full donor chimerism and one had autologous hematopoiesis. Grade 2 HSCT-associated acute GVHD occurred in three patients. During a median of 15.1 months of follow-up after CAR T-cell therapy, six patients remained in minimal residual disease-negative complete remission, two had CD7-negative leukemia relapse, and one died of septic shock (at 3.7 months). Estimated one-year overall survival and one-year disease-free survival were 68 and 54 percent, respectively.
"Our integrated strategy maximized antileukemic efficacy from both persisting CAR T cells and graft-versus-leukemia potential, providing a feasible approach for patients with relapsed or refractory CD7-positive cancers who are ineligible for conventional allogeneic HSCT," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Vaginal Cancer Incidence Increasing Globally
WEDNESDAY, July 3, 2024 -- The incidence of vaginal cancer is increasing globally, according to a study published online June 25 in BJOG: An International Journal of Obstetrics...
Nudging Both Clinicians, Patients May Increase Serious Illness Conversations
TUESDAY, July 2, 2024 -- Combining clinician- and patient-directed nudges may help to promote serious illness conversations (SICs) in cancer care, according to a study published...
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.